Additional file 6: Tables S11-S20. of Eligibility of real-life patients with COPD for inclusion in trials of inhaled long-acting bronchodilator therapy

Distribution of inclusion criteria in the Optimum Patient Care Research Database (OPCRD) population. Table S12. Distribution of COPD-related exclusion criteria in the population of patients with COPD in the Optimum Patient Care Research Database (OPCRD). Table S13. Distribution of concomitant pulmonary diseases in the population of patients with COPD in the Optimum Patient Care Research Database (OPCRD). Table S14. Distribution of asthma, allergic diseases and atopy in the population of patients with COPD in the Optimum Patient Care Research Database (OPCRD). Table S15. Distribution of other comorbidities in the population of patients with COPD in the Optimum Patient Care Research Database (OPCRD). Table S16. Distribution of other relevant conditions in the population of patients with COPD in the Optimum Patient Care Research Database (OPCRD). Table S17. Distribution of contra-indications in the population of patients with COPD in the Optimum Patient Care Research Database (OPCRD). Table S18. Percentage of Optimum Patient Care Research Database (OPCRD) patients with COPD and mMRC ≥2 who would be eligible for RCTs testing tiotropium (n = 17 075). Table S19. Percentage of Optimum Patient Care Research Database (OPCRD) patients with COPD and mMRC ≥2 (n = 17 075) who would be eligible for RCTs testing formoterol (F), aclidinium (A), indacaterol (I), olodaterol (O) and glycopyrronium (G). Table 20. Percentage of Optimum Patient Care Research Database (OPCRD) patients with COPD and mMRC ≥2 (n = 17 075) who would be eligible for RCTs testing indacaterol + glycopyrronium (I + G), vilanterol + umeclidinium (V + U) and tiotropium + olodaterol (T + O). (DOCX 27 kb)